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Background: This study explores spirometry quality and reproducibility in the Understanding
Potential Long-term Impacts on Function with Tiotropium (UPLIFT) trial.
Methods: Four-year, randomized, double-blind, placebo-controlled, multicenter trial in 5993
patients with chronic obstructive pulmonary disease. Within-test variability of pre- and
post-bronchodilator forced expiratory volume in 1 s (FEV1) was compared across study visits.
Between-test variability of best pre- or post-FEV1 values between two visits 6 months apart
was compared at the start, middle and end of the trial.
Results: Three or more acceptable maneuvers were obtained in 93% of visits. Within-test vari-
ability of pre- and post-FEV1 (mean standard deviation: 0.092 and 0.098 L) decreased during
the trial. Between-test variability also decreased: pre-FEV1 (visit 3e5Z 0.141  0.138 L; visit
9e11 Z 0.129  0.121 L; visit 17e19 Z 0.121  0.122 L); post-FEV1 (0.139  0.140,
0.126  0.123, 0.121  0.122 L, respectively), and was dependent on age, sex, smoking status
and disease stage, but not on bronchodilator response or study treatment.Division, Department of Pneumology, University Hospital Leuven, Herestraat 49, 3000 Leuven,
32 1634 6803.
zleuven.be, wim.janssens@med.kuleuven.be (W. Janssens).
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1410 W. Janssens et al.Conclusion: Spirometry quality in UPLIFT was good and improved during the trial. Between-
test variability across patient subgroups suggests that relevant cut-offs for individual disease
monitoring are difficult to establish.
Trial registration number: NCT00144339.
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International guidelines recognize spirometry as the gold
standard for diagnosing, categorizing and monitoring disease
progression in chronic obstructive pulmonary disease
(COPD).1 Within a spirometry session, a valid test is defined
by three technically acceptable and reproducible forced
expiratory volume in 1 s (FEV1) and forced vital capacity (FVC)
maneuvers.2,3 The largest FVC and the largest FEV1 should be
recorded after examining the data from all of the acceptable
time/volume curves, even if they do not come from the same
curve; reproducibility is defined as the difference between
the highest and second-highest FVC and FEV1 from accept-
able curves.2 The spirometry standardization paper of the
American Thoracic Society (ATS) and the European Respira-
tory Society (ERS) states that a variance of0.15 L in the two
largest values of FEV1 or FVC meets reproducibility criteria
(or 0.1 L, where FVC is 1 L).3 Earlier ATS criteria allowed
for 0.2 L difference.2 If these criteria are not met in three
maneuvers, up to a total of eight maneuvers should be
attempted to meet the minimal requirements. Standardiza-
tion is essential to obtain the “true” spirometric valueswithin
one session, particularly for COPD trials evaluating small
differences in lung function as primary outcomes.
Between-test variability may be greater than within-test
variability, owing to technical differences in the testing
procedures (including equipment variability), or intra-
patient factors such as the degree of airway obstruction,
changes in bronchomotor tone, diurnal variation in FEV1,
baseline FEV1 levels or bronchodilator reversibility.
4e7
Other factors that may affect test performance include
smoking, medication use or recent illness.2,3 Previous data
have shown mean between-test differences of 0.1  0.1 L
for FEV1.
7e9 Confounding variability in spirometry must be
minimized in COPD trials, as there may be little difference
in lung function decline over time between active treat-
ment and control groups.5,10,11 Additionally, between-test
variance should be considered when using spirometry for
individual patient monitoring. Yet there are no specific
recommendations for thresholds defining a clinically rele-
vant difference in FEV1 between spirometry sessions.
6,7
The Understanding Potential Long-term Impacts on
Function with Tiotropium (UPLIFT) trial was a 4-year, ran-
domized, double-blind, placebo-controlled study conducted
in 487 study centers in 37 countries.11 To ensure high-quality
spirometry, diurnal variation was minimized, all sites were
provided with the same training and electronic data trans-
mission provided study staff with automated, real-time
feedback on the quality and reproducibility of the measure-
ments via a centralized quality assurance review.5 Therefore,
the UPLIFT database represents a unique opportunity to
perform post hoc evaluation of quality and reproducibility of
spirometric measurements in COPD patients.Methods
Study design and population
UPLIFT was a 4-year, randomized, placebo-controlled
clinical trial of tiotropium in 5993 patients with COPD
(ClinicalTrials.gov number, NCT00144339.).11 Details of the
UPLIFT study design can be found in the online depository.
All patients gave written informed consent. The study was
approved by local ethical review boards and conducted in
accordance with the Declaration of Helsinki.
Spirometry assessments
To standardize spirometry, all sites were provided with
identical spirometry systems (KoKo Spirometer, Quantum
Research Inc., Louisville, CO, USA) with customized, study-
specific software. All technicians performing pulmonary
function testing received identical, detailed training and
were required to show proficiency in using the equipment
and performing technically acceptable pulmonary function
tests, before testing study patients. After each test was
performed, the spirometry software gave immediate feed-
back to the technician to show whether the maneuver met
ATS acceptability and reproducibility standards. All data
were stored electronically.5 Details of the spirometry data
quality assurance methods used are in the online depository.
To reduce diurnal variation in FEV1, spirometry was
performed at approximately the same time in the morning
at screening (baseline, visit 1), on randomization to treat-
ment (day 1, visit 2), on day 30 (visit 3) and then every 6
months (at visits 5, 7, 9, 11, 13, 15, 17 and 19) until the end
of treatment. A final test was performed at the 30-day post-
treatment follow-up visit (end of trial).
Post-bronchodilator spirometry was performed at the
90-min time point. Detailed information on the spirometry
protocol can be found in the online depository. FEV1 and
FVC measurements were obtained in triplicate following
slow vital capacity measurement. The best FEV1 and FVC
values of three attempts meeting ATS reproducibility
criteria (5% or 0.2 L, current at the time of trial design)2
were recorded for the data set.
Statistical analysis
All analyses were restricted to visits with at least three
acceptable maneuvers.
Within-test variability of pre- and post-bronchodilator
FEV1 was assessed by using the following model at each
visit: Yik Z mean FEV1 þ bi þ eik (where Yik Z acceptable
maneuvers, ik Z kth maneuver of the ith subject,
bi Z random individual effect accounting for between-
Table 1 Baseline characteristics of patients in the
UPLIFT trial.
Tiotropium
(n Z 2986)
Control
(n Z 3006)
Age, y 64.5  8.4 64.5  8.5
Male, % 75.4 73.9
BMI, kg/m2 26.0  5.1 25.9  5.1
Smoking status
Current smokers, % 29.3 29.9
History, pack-years 49.0  28.0 48.4  27.9
COPD duration, y 9.9  7.6 9.7  7.4
Baseline spirometry
Pre-bronchodilator
FEV1, L 1.10  0.4 1.09  0.40
FEV1, % predicted 39.5  12.0 39.3  11.9
FVC, L 2.63  0.8 2.63  0.8
FEV1/FVC 42.4  10.5 42.1  10.5
Post-bronchodilator
FEV1, L 1.33  0.4 1.32  0.4
FEV1, % predicted 47.7  12.7 47.4  12.6
FVC, L 3.09  0.9 3.09  0.9
FEV1/FVC 43.6  10.8 43.3  10.7
GOLD stage, %
II 46 45
III 44 44
IV 8 9
SGRQ total score, units 45.7  17.0 46.0  17.2
Concomitant medications, %
SABAa 68.5 68.1
LABAa 60.1 60.1
SAACa 44.9 44.1
LAACa 2.0 1.6
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accounting for within-test variability). Within-test vari-
ability was also assessed by calculating the population
mean of differences between best, second- and third-best
FEV1 measurement of one session at every study visit
(Fig. 1), which was then compared across study visits.
Between-test variability was calculated as the mean of
the absolute difference in best pre- or post-bronchodilator
FEV1 (DjFEV1j) values between two visits made 6 months
apart, and corrected for a normal FEV1 decline of 15 mL, at
the start of the trial (visits 3e5),middle (visits 9e11) and end
(visits 17e19) (Fig. 1). The correction of 15 mL over 6 months
(DjFEV1j  15 mL) was assumed due to the observed mean
decline of30 mL/year in UPLIFT. To avoid confounding by
early discontinuation, the analysis was restricted to patients
withmeasurements at all visits. Between-test variability was
compared over time between different strata according to
sex (male/female), smoking behavior (current/ex-smoker),
treatment arm (tiotropium/control), Global Initiative for
Chronic Obstructive Lung Disease (GOLD) stage (I and II, III,
IV), age (<55, 55 to<65, 65 to<75,75 years),magnitude of
bronchodilator response (50, 50 to 100, 100 to 150, 150
to 200, >200 mL) and region (Asia, Eastern Europe, Latin
America, USA, Western Europe) using two-way analysis of
variance that includes interaction between time period and a
subgroup variable. Between-test variability was also
analyzed by a multivariate linear model including time
period, all subgroup variables (gender, age, smoking
behavior, treatment, acute bronchodilator response, GOLD
stage and region), and with second-degree interaction for
time period with all subgroup variables. Mean difference of
best pre- or post-bronchodilator FEV1 values between two
consecutive visits (FEV1 [visit x þ 1]  FEV1 [visit x]) are
expressed as d(FEV1)  standard deviation (SD). Minimally
important changes of FEV1 were defined by 1.64 SD as they
express the minimal change of FEV1 needed for a likelihood
of 90% to represent a true change of FEV1 between two
consecutive tests at a 6-month interval.
Results
Baseline characteristics of population and
spirometry
A total of 5993 patients were enrolled in UPLIFT;
5992 were randomized and received study medicationFigure 1 Schematic representation of the assessment of
within- and between-test variability of spirometry in the
UPLIFT trial. UPLIFT Z Understanding Potential Long-term
Impacts on Function with Tiotropium.(tiotropium, n Z 2986; control, n Z 3006). Baseline char-
acteristics are summarized in Table 1. A minimum number
of three acceptable measurements were obtained in 93%
of pre-bronchodilator sessions and in 94% of post-
bronchodilator sessions, with no significant difference in
these proportions between study visits (Table 2). In 70% of
visits, only three acceptable spirometry maneuvers
were acquired, with a mean of 3.5  0.03 maneuvers per
visit for pre-bronchodilator spirometry (acceptability
within correct spirometry of 86%). In 23% of visits, more
than three acceptable spirometry maneuvers were regis-
tered, with a mean of 4.8  0.06 maneuvers per visit forICSa 61.6 61.9
OCS 8.4 8.3
Theophylline compound 28.4 28.5
Data are mean  SD unless otherwise indicated.
BMIZ Body mass index; COPDZ Chronic obstructive pulmonary
disease; FEV1Z Forced expiratory volume in 1 s; FVCZ Forced
vital capacity; GOLDZ Global Initiative for Chronic Obstructive
Lung Disease; ICSZ Inhaled corticosteroid; LAACZ Long-acting
anticholinergic; LABA Z Long-acting b2-agonist; OCS Z Oral
corticosteroid; SAAC Z Short-acting anticholinergic;
SABA Z Short-acting b2-agonist; SD Z Standard deviation;
SGRQ Z St. George’s Respiratory Questionnaire;
UPLIFT Z Understanding Potential Long-term Impacts on
Function with Tiotropium.
a Used alone or in combination.
Table 2 Acceptability of spirometry in the UPLIFT trial.
Pre-bronchodilator
Patients with exactly
3 acceptable maneuvers
Patients with more than
3 acceptable maneuvers
Patient with greater than or equal
to 3 acceptable maneuvers
n Proportion n Proportion n Proportion
Visit 3 4007 0.71 1299 0.23 5306 0.94
Visit 5 3719 0.70 1220 0.23 4939 0.93
Visit 7 3454 0.69 1207 0.24 4661 0.93
Visit 9 3323 0.72 1055 0.23 4378 0.95
Visit 11 3065 0.71 966 0.22 4031 0.93
Visit 13 2867 0.70 899 0.23 3766 0.93
Visit 15 2666 0.69 885 0.23 3551 0.92
Visit 17 2495 0.68 880 0.24 3375 0.92
Visit 19 2434 0.70 806 0.23 3240 0.93
Post-bronchodilator
Patients with exactly
3 acceptable maneuvers
Patients with more than
3 acceptable maneuvers
Patient with greater than or equal
to 3 acceptable maneuvers
n Proportion n Proportion n Proportion
Visit 3 4046 0.72 1267 0.23 5313 0.95
Visit 5 3803 0.72 1140 0.22 4943 0.94
Visit 7 3558 0.72 1098 0.22 4656 0.94
Visit 9 3326 0.72 1064 0.23 4390 0.95
Visit 11 3100 0.72 942 0.22 4042 0.94
Visit 13 2866 0.70 907 0.22 3773 0.92
Visit 15 2743 0.71 853 0.22 3596 0.93
Visit 17 2593 0.72 786 0.22 3379 0.94
Visit 19 2450 0.71 803 0.23 3253 0.94
Proportion is the number of patients who have 3 acceptable measurements over patients with 1 acceptable measurement.
UPLIFT Z Understanding Potential Long-term Impacts on Function with Tiotropium.
1412 W. Janssens et al.pre-bronchodilator spirometry (acceptability within correct
spirometry of 92%). The mean number of maneuvers
required to obtain at least three acceptable maneuvers did
not differ significantly over the different study visits.
Similar findings were obtained for post-bronchodilator
spirometry (e-Table 1aeb in online depository).
Within-test variability in FEV1
The mean difference between the best and second-best
pre-bronchodilator FEV1 value within one session ranged
from 0.036 to 0.042 L over the different study visits, with an
average of 0.038 L. The mean difference between the best
and third-best pre-bronchodilator FEV1 value within one
session varied between 0.079 and 0.088 L over the study
visits, with an average of 0.084 L; for post-bronchodilator
FEV1, similar values were obtained (Fig. 2). The mean
within-test variability (SD) from the different visits for
pre- and post-bronchodilator FEV1 values was 0.092  0.006
and 0.099  0.005 L, respectively. Within-test variability
increased from visit 3 to visit 7 and showed a decreasing
trend after visit 7 until the end-of-treatment visit (visit 19),
suggesting a learning effect over the course of the trial
(Fig. 3). A similar analysis was performed in patients with
spirometry measurements at all visits (n Z 3257). Popula-
tion characteristics of this subgroup are given in e-Table 2of the online depository. Again, within-test variability
followed the same decreasing trend across study visits (see
e-Fig. 1).
Between-test variability in FEV1
In the population of patients with at least three acceptable
measurements at every study visit (n Z 3257), between-
test variability (mean  SD) of pre-bronchodilator FEV1
decreased from 0.141  0.138 L at the beginning of the trial
(visits 3e5), to 0.129  0.121 L by visits 9e11 and
0.121  0.122 L at the end of the trial (visits 17e19)
(p < 0.0001) (Table 3). There was no statistically significant
difference in between-test variability for pre- versus post-
bronchodilator FEV1 values (p Z 0.39).
Multivariate analysis of between-test variability of pre-
bronchodilator FEV1 between different subgroups showed
that between-test variability was associated with age
(p < 0.0001), sex (p < 0.0001), smoking status (p Z 0.008)
and COPD severity/GOLD stage (p Z 0.0001), but was not
affected by treatment (tiotropium/control) (p > 0.05)
(Table 4). When categorizing according to bronchodilator
response, statistically significant differences were present
between certain subgroups, but without any consistency
among study visits and with no relationship to the level of
bronchodilator response. When comparing between-test
Figure 2 Differences between best and second- or third-best pre- and post-bronchodilator FEV1 of Accepted spirometry ma-
neuvers. Data represent mean population values with 95% confidence intervals. FEV1 Z forced expiratory volume in 1 s.
Quality and reproducibility of spirometry in COPD 1413variability of different regions, the largest difference could
be found between patients from Asia and Eastern Europe,
whereas Latin America, USA and Western Europe had rela-
tively similar values that were not statistically different
from each other. Multivariate analysis confirmed that irre-
spective of time period, factors such as age, sex, smoking
status, GOLD stage, region and bronchodilator response
were highly significant, independent predictors for
between-test variability. Treatment arm as a predictor was
nominally significant at the level of p < 0.05 (p Z 0.042).
Population mean difference between the best pre-
bronchodilator FEV1 measurement at the 6-month interval
[d(FEV1)] varied from 0.001 L at the beginning of the trial
to 0.018 L in the middle and 0.016 L at the end of the trial,
indicating that the anticipated correction of 0.015 L for
FEV1 decline over 6 months was appropriate (Table 5).Figure 3 Within-test variability of pre-bronchodilator FEV1 f
SD Z standard deviation.Minimally important changes in FEV1, as defined by
1.64  SD of d(FEV1), were in the range of 0.282e0.323 L
for both pre- and post-bronchodilator measurements and
were dependent on the time period of evaluation (Table 5).Discussion
The spirometry quality in UPLIFT was good, and further
improved on trial progression. In 93% of visits, good spiro-
metric measurements were obtained according to former
ATS guidelines, with a mean of 86e92% of maneuvers
correctly performed. The number of acceptable spiro-
metric measurements and maneuvers needed did not differ
during the study, indicating that a certain percentage
of failed maneuvers will occur, despite training andor visits 3e19. FEV1 Z forced expiratory volume in 1 s;
Table 3 Between-test variability during the trial.
Time point Mean  SD change, L
Pre-bronchodilator FEV1 Post-bronchodilator FEV1
Visit 3e5 (n Z 3251) 0.141  0.138 (n Z 3251) 0.139  0.140
Visit 9e11 (n Z 3248) 0.129  0.121 (n Z 3249) 0.126  0.123
Visit 17e19 (n Z 3254) 0.121  0.122 (n Z 3239) 0.121  0.122
Two-way analysis of variance: p < 0.0001 for time period; pZ 0.39 for bronchodilator status; pZ 0.78 for interaction. FEV1Z Forced
expiratory volume in 1 s; SD Z Standard deviation.
1414 W. Janssens et al.experience. The 6.9% of visits in which the standard of
spirometry did not meet ATS criteria is higher than the 2.1%
of failures reported for the Lung Health Study that included
much younger subjects (<60 years) with less severe dis-
ease, and a more restricted geographical range than
UPLIFT.10 We have no insight into similar data of other
long-term intervention trials.12,13Table 4 Between-test variability in different subgroups.
Subgroup Mean  SD change in pre-bronch
Visits 3e5 Visits 9e11
Sex
Male (n Z 2477) 0.149  0.143 0.135  0.125
Female (n Z 774) 0.113  0.116 0.108  0.106
Smoking status
Current smoker (n Z 936) 0.151  0.147 0.140  0.124
Ex-smoker (n Z 2315) 0.137  0.134 0.125  0.120
Treatment arm
Tiotropium (n Z 1714) 0.142  0.141 0.130  0.128
Control (n Z 1537) 0.140  0.135 0.127  0.115
COPD severity (GOLD stage)
I or II (n Z 1698) 0.154  0.148 0.142  0.123
III (n Z 1326) 0.128  0.126 0.116  0.105
IV (n Z 179) 0.100  0.097 0.088  0.095
Age, y
<55 (n Z 478) 0.161  0.169 0.145  0.138
55 to <65 (n Z 1232) 0.148  0.143 0.134  0.122
65 to <75 (n Z 1257) 0.130  0.125 0.122  0.114
75 (n Z 284) 0.126  0.111 0.110  0.110
Bronchodilator response, mL
<50 (n Z 355) 0.146  0.150 0.123  0.110
50 to 100 (n Z 260) 0.109  0.109 0.108  0.094
100 to 150 (n Z 371) 0.137  0.141 0.119  0.109
150 to 200 (n Z 379) 0.124  0.121 0.117  0.106
>200 (n Z 1786) 0.148  0.140 0.137  0.128
Region
Asia (n Z 196) 0.114  0.099 0.095  0.082
Eastern Europe (n Z 785) 0.167  0.162 0.150  0.140
Latin America (n Z 254) 0.144  0.147 0.119  0.111
USA (n Z 699) 0.127  0.117 0.126  0.120
Western Europe (n Z 1317) 0.136  0.135 0.125  0.114
Univariate p-values reflect statistical differences between subgroups
values reflect statistical differences between subgroups corrected for
p > 0.05). COPDZ Chronic obstructive pulmonary disease; FEV1Z For
Obstructive Lung Disease; SD Z Standard deviation.The variability of maneuvers within a valid spirometry
session was assessed by mean DFEV1 and within-test vari-
ability. The mean difference between the best and second-
best FEV1 measurement in an adequate UPLIFT
 spirometry
session was very similar to those reported in the Lung
Health Study.10 In our study, within-test variation showed a
progressive decrease during the trial, even among the largeodilator FEV1, L
Visits 17e19 Univariate p-value Multivariate p-value
0.127  0.126 <0.0001 <0.0001
0.100  0.103
0.133  0.137 <0.0001 0.008
0.115  0.115
0.124  0.118 0.12 0.042
0.117  0.126
0.133  0.132 0.0001 0.0001
0.110  0.110
0.083  0.087
0.144  0.144 <0.0001 <0.0001
0.121  0.119
0.117  0.114
0.100  0.119
0.128  0.124 <0.0001 0.015
0.106  0.098
0.105  0.103
0.112  0.103
0.127  0.131
0.083  0.084 <0.0001 <0.001
0.138  0.138
0.113  0.103
0.124  0.120
0.115  0.118
(time period: p < 0.0001, interaction p > 0.05). Multivariate p-
all other subgroup variables (time period: pZ 0.029, interaction
ced expiratory volume in 1 s; GOLDZ Global Initiative for Chronic
Table 5 Between-test difference e d(FEV1) e and MIC of
FEV1 (L) between two consecutive visits at 6-month
intervals.
Pre-bronchodilator Post-bronchodilator
d(FEV1)
(mean  SD, L)
MIC
(L)
d(FEV1)
(mean  SD, L)
MIC
(L)
Visit 3e5 0.001  0.197 0.323 0.001  0.197 0.323
Visit 9e11 0.018  0.177 0.290 0.027  0.176 0.288
Visit
17e19
0.016  0.172 0.282 0.025  0.172 0.282
FEV1 Z Forced expiratory volume in 1 s; MIC Z Minimally
important changes; SD Z Standard deviation.
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every visit. This conservative subgroup analysis was con-
ducted to reduce the selection bias that may have been
caused by the early discontinuation of patients with high
within-test variability and suggests that the observed
improvement most likely relates to experience and
training. Education and training of patients and staff prior
to trial initiation is therefore mandatory.
Mean between-test variability was significantly influ-
enced by the time period of evaluation. It decreased from
0.141  0.138 to 0.121  0.122 L, suggesting that training
may also reduce between-session variation. In the Lung
Health Study, slightly lower values were reported
(0.110  0.10 L), whereas absolute differences between
two consecutive spirometry sessions were much smaller in
the National Emphysema Treatment Trial (NETT)
(0.089  0.080 L).7 Different study populations may ac-
count for this discrepancy, as we showed that covariates
including disease severity significantly affect between-test
variability. This is corroborated by the observation that the
between-test variability of the most severe patients in
UPLIFT was comparable with those of NETT.11,14 Another
explanation may be that although we corrected for a pop-
ulation mean decline of 0.015 L for 6 months in UPLIFT,
the prolonged time interval to the second measurement
may have been more subject to external factors such as
concurrent exacerbations. Further investigation would be
required to test this hypothesis.
In UPLIFT, significant predictors of between-test vari-
ability emerged independently of time of evaluation and
after multivariate analysis; this suggests that the observed
relationships with age, gender, smoking status, COPD
severity and ethnicity are robust. The standard correction
of 15 mL for FEV1 decline may not be ideal when comparing
subgroups with a known difference in decline. However, the
difference of between-test variability between subgroups
largely exceeded the potential difference in 6-month
decline. Moreover, it will be hard to correct for a
different decline in subgroups as many factors including
age, gender, smoking status and medication may affect
this. Previous studies showed that short-term between-test
variability is also dependent on airway hyperreactivity and
bronchodilator response.4,8,15 Surprisingly, we found that
both patients with highest and those with lowest broncho-
dilator responses, including those with a paradoxicaldecrease in post-bronchodilator FEV1, showed the largest
between-test variability. The reasons for this are unclear,
although similar findings in paradoxical responders have
been reported previously.8 In contrast to the data of Herpel
et al.,7 we also found a consistent reduction in absolute
between-test variability of approximately 40% between
GOLD stage I/II and IV at any given time point. Differential
study populations may also contribute to this discrepancy.
As short-term between-session variability largely ex-
ceeds the expected annual decline of FEV1, repeated FEV1
measurements over several years in a large number of
subjects are needed to achieve sufficient confidence in
estimating the mean FEV1 decline of populations in clinical
trials.5 In clinical practice however, it is hard to predict
whether short-term between-session variability in one in-
dividual patient is within the normal range of variation or
whether it reflects clinically important changes. The mini-
mally important change values are not the appropriate tool
to identify changes in FEV1 that affect symptoms. As normal
variation may also have clinical significance in terms of
symptoms, our statistical cut-offs rather represent changes
in FEV1 that are true and representative of real deteriora-
tion or improvement of pulmonary function on the indi-
vidual level. Although Herpel et al. suggested that FEV1
changes >0.225 L likely represent true changes in lung
function,7 we demonstrated that changes greater than
0.280e0.320 L would be required to exceed the normal
between-test variation. However, FEV1 changes over time
are biased by training in spirometry and patient charac-
teristics, while changes within the normal variation may
still represent a clinically meaningful result when accom-
panied by symptom changes.16 Therefore, some experts
have suggested that the minimal clinically important dif-
ference between two measurements is best estimated by
the standard error, which would be around 0.180 L for
UPLIFT.6,17
It is possible that differences in spirometry measurements
or the instruments used may lead to confounding variance in
the data collected between the numerous sites of large-
scale studies, such as UPLIFT.18,19 As the UPLIFT trial was
conducted across 487 sites, it was important to employ
standardized spirometry methodology, including identical
systems and training for all technicians, and customized,
study-specific software. These control measures reduced the
likelihood of variability caused by inter-center differences in
the recording or analysis of lung function data.
In conclusion, the quality of spirometry during the
UPLIFT trial was acceptable and further improved over
time, as shown by a reduction in within-test and between-
test variability. These data are an example of the accuracy
of the standardized methodology used in a large, random-
ized, controlled trial. Considerable between-test variability
was observed in accordance with patient age, sex, smoking
status, region and COPD severity.Conflict of interest statement
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